This came after Bayer Pharmaceutical presented the proposal for a grant of permission to import and market the drug ...

Telangana: Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the ...

Aurobindo Pharma Ltd - Curateq Biologics Received Marketing Authorization For Dyrupeg???, A Pegylated Filgrastim Biosimilar Intimation of receipt of Marketing authorisation by Curateq Biologics s.r.o, ...

Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds. They include antisense oligonucleotides, aptamers and small interfering RNAs, and are typically ...

Palynziq substitutes the deficient phenylalanine hydroxylase (PAH) enzyme in PKU with a PEGylated version of the enzyme ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B ...

The global interferons market is on a steady growth trajectory, with its valuation projected to surge from USD 9.4 billion in 2022 to USD 13.8 billion by 2032. According to a recent report by Future ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders through targeted drug delivery.

Serina Therapeutics (SER) announced that Randall Moreadith, CDO, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, ...